Bioengineering

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March) DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode three, Connecting lab automation to decision-making. In this episode, we hear from Ashwin Pillai, a Test Engineer […]

University of Queensland researchers have pioneered a new chemical process to manufacture molecules that are the building blocks for lifesaving medicines, vaccines and energy storage materials. Professor Matt Trau from UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded an ARC Laureate Fellowship worth $2.9 million to further understand and develop the process. […]

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why they have been fruitful, and […]

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of physiologically relevant cells from validated […]

17 July 2020 Removing memories associated with morphine use from the brains of mice enables Stanford researchers to prevent relapse and could point to a new approach for treating the opioid epidemic. By Lara Streiff Research surrounding addiction often assumes reward is the primary motivation for drug use and relapse. But while chasing a “high” […]

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28 other off-target moieties. However, the […]

3D Cell Culture – Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery By Dr Patrick Guye, Dr Eva Thoma and Dr Olivier Frey In this article, we will share some of what we have learned over the past 10 years as pioneers in the 3D cell culture space and provide guidance for those who […]

The Future Of Drug Discovery – Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds, acting alone or in combination, […]

Induced Pluripotent Stem Cells (iPSCs) – Unlocking their full potential for Drug Discovery By Abby Edwards and Dr Richard Massey Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies and protocols mean that induced pluripotent stem cells (iPSCs) are now playing an increasingly important […]

Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined […]